A Study of Biofluids in Parkinson Disease and Related Disorders

Overview

About this study

The purpose of this study is to analyze DNA and genome-wide analyses, as well as metabolomics and biomarker studies, from patients in the spectrum clinically diagnosed Parkinson disease, Lewy Body disease and related diseases. This would include persons experiencing the earliest manifestations to those with established Parkinsonism. 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • An adult with any symptomatic disorder clinically diagnosed as Lewy Bodies, Parkinson disease dementia, Progressive Supranuclear Palsy, Multiple System Atrophy.

Exclusion Criteria

  • An alternative diagnosis (including but not limited to: major head trauma, major psychiatric disorder, major systemic illness, substantial cerebrovascular disease) likely to be playing a substantial role in the manifestations of the parkinsonism.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Rodolfo Savica, M.D., Ph.D.

Open for enrollment

Contact information:

Sandra Looney B.S.

(507) 538-4107

Looney.Sandra@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available